Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus

Diabetologia. 2002 Mar;45(3):420-6. doi: 10.1007/s00125-001-0760-y.

Abstract

Aim/hypothesis: We assessed whether dietary supplementation with coenzyme Q(10) improves endothelial function of the brachial artery in patients with Type II (non-insulin-dependent) diabetes mellitus and dyslipidaemia.

Methods: A total of 40 patients with Type II diabetes and dyslipidaemia were randomized to receive 200 mg of coenzyme Q(10) or placebo orally for 12 weeks. Endothelium-dependent and independent function of the brachial artery was measured as flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation, respectively. A computerized system was used to quantitate vessel diameter changes before and after intervention. Arterial function was compared with 18 non-diabetic subjects. Oxidative stress was assessed by measuring plasma F(2)-isoprostane concentrations, and plasma antioxidant status by oxygen radical absorbance capacity.

Results: The diabetic patients had impaired flow-mediated dilation [3.8 % (SEM 0.5) vs 6.4 % (SEM 1.0), p = 0.016], but preserved glyceryl-trinitrate-mediated dilation, of the brachial artery compared with non-diabetic subjects. Flow-mediated dilation of the brachial artery increased by 1.6 % (SEM 0.3) with coenzyme Q(10) and decreased by -0.4 % (SEM 0.5) with placebo (p = 0.005); there were no group differences in the changes in pre-stimulatory arterial diameter, post-ischaemic hyperaemia or glyceryl-trinitrate-mediated dilation response. Coenzyme Q(10) treatment resulted in a threefold increase in plasma coenzyme Q(10) (p < 0.001) but did not alter plasma F(2)-isoprostanes, oxygen radical absorbance capacity, lipid concentrations, glycaemic control or blood pressure.

Conclusion/interpretation: Coenzyme Q(10) supplementation improves endothelial function of conduit arteries of the peripheral circulation in dyslipidaemic patients with Type II diabetes. The mechanism could involve increased endothelial release and/or activity of nitric oxide due to improvement in vascular oxidative stress, an effect that might not be reflected by changes in plasma F(2)-isoprostane concentrations.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants / therapeutic use*
  • Blood Pressure / drug effects
  • Brachial Artery / drug effects
  • Brachial Artery / physiopathology*
  • Cholesterol / blood
  • Coenzymes
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Diabetic Angiopathies / prevention & control*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology*
  • Female
  • Humans
  • Hyperemia / prevention & control
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Placebos
  • Regional Blood Flow / drug effects
  • Triglycerides / blood
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / therapeutic use*
  • Vasodilation / drug effects

Substances

  • Antioxidants
  • Coenzymes
  • Lipoproteins
  • Placebos
  • Triglycerides
  • Ubiquinone
  • Cholesterol
  • coenzyme Q10